SLC9A1 and heart disorder: Despite the enormous potential of NHE antagonists as cardioprotective agents, these serious side effects have precluded further development of NHE‐1 antagonists for treatment of heart disease and called for preclinical studies to identify potential mechanisms underlying the increased cerebrovascular events in patients treated with these compounds.